Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabusertib with Pemetrexed and Cisplatin in Stage IV NSCLC
NCT01139775Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rabusertib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Feb 2011; status: completed.
02
Drugs
rabusertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01139775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01139775.